Brain Research and Integrative Neuroscience Network for COVID-19 (BRAINN)
Brain Research and Integrative Neuroscience Network for COVID-19 (BRAINN)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The two intervention protocols (digitalized CP and NIBS) required for this study have been developed and the required equipment (one existing and three new tDCS devices) has been acquired. Recruitment for the feasibility study is planned to begin in month 18, i.e., June 2024.
Changes in the design of the feasibility study have been made by the SC and in coordination with the Advisory Board. The changes were deemed necessary to improve the original study design to capture changes in cognition due to treatment. Specifically, the feasibility study will retain the two-group design (experimental and control). Forty participants with PCS will be recruited (instead of seventy, as originally planned). All participants will undergo the diagnostic protocols (the neuroimaging and neuropsychological assessments). Then, participants will be randomly assigned into two groups: the experimental, who will receive the active tDCS and CP intervention, and the control group, who will receive the sham tDCS and CP intervention. Following the intervention, all participants (experimental and control) will complete a series of dependent measures, including neuropsychological performance and quality of life measures. For neurophysiological measures, electroencephalography (EEG) has been replaced with functional near-infrared spectroscopy (fNIRS), which will be conducted both pre- and post-intervention. The current design will require a longer intervention period (as compared to the original design) and the complete delivery of the digitalized CP to maximize treatment effectiveness.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Fofi Constantinidou, Ph.D.
- Phone Number: +357 22892078
- Email: fofic@ucy.ac.cy
Study Contact Backup
- Name: Eleni Michael
- Phone Number: +35722895190
- Email: can@ucy.ac.cy
Study Locations
-
-
Cyprus
-
Nicosia, Cyprus, Cyprus, 1678
- University of Cyprus
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Reported cognitive difficulties due to COVID-19 infection
- WHO Long COVID criteria will be used
Exclusion Criteria:
- Significant history of neuropsychiatric conditions prior to contracting COVID-19; history of neurological conditions such as TBI, CVA, MS prior to contracting COVID-19.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Sham Comparator: Control Condition
Combination of cognitive training with sham tDCS
|
Participation in 15 one-hour sessions distributed over five weeks.
During each session participants will receive cognitive training with the Categorization Program and sham tDCS
|
|
Experimental: Experimental Condition
Combination of cognitive training with active tDCS
|
Participation in 15 one-hour sessions distributed over five weeks.
During each session participants will receive cognitive training with the Categorization Program and sham tDCS
Participation in 15 one-hour sessions distributed over five weeks.
During each session participants will receive two sessions of tDCS plus cognitive training with the Categorization Program
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Categorization Program Test 1
Time Frame: Administered pre & post training with the Categorization Program, at 6 weeks
|
Semantic knowledge and classification behavior
|
Administered pre & post training with the Categorization Program, at 6 weeks
|
|
Categorization Program Test 2
Time Frame: Administered pre & post training with the Categorization Program, at 6 weeks
|
Decision-Making and Rule based learning
|
Administered pre & post training with the Categorization Program, at 6 weeks
|
|
Probe Tasks
Time Frame: Administered pre testing, at 2 weeks, 3 weeks and after completion of training at 6 weeks
|
Decision-Making and Rule based learning
|
Administered pre testing, at 2 weeks, 3 weeks and after completion of training at 6 weeks
|
|
WHO BREF Quality of Life
Time Frame: before and after training, at 6 weeks
|
general quality of life
|
before and after training, at 6 weeks
|
|
Dysexecutive Questionnaire
Time Frame: pre and post training, at 6 weeks
|
Test of everyday executive functioning behaviors; self and informant reports
|
pre and post training, at 6 weeks
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cognitron Cognitive Assessment Battery
Time Frame: Pre & Post Testing, after completion of training at 6 weeks
|
Tests of memory, reaction time, and executive Functioning
|
Pre & Post Testing, after completion of training at 6 weeks
|
|
fNIRS
Time Frame: pre and post training testing, after completion of training at 6 weeks
|
Functional spectroscopy of oxygenated and deoxygenated hemodynamic responses
|
pre and post training testing, after completion of training at 6 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Fofi Constantinidou, Ph.D., University of Cyprus
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 101079001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.